Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 9Urinary Bladder Neoplasms 4Urethral Neoplasms 4Melanoma 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Carcinoma, Hepatocellular 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Penile Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Lung Neoplasms 2HIV Infections 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 6Biopsy 5Paclitaxel 4pembrolizumab 3Platinum 3Immunoglobulin G 3Disulfides 3Cetuximab 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cemiplimab 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Radiation 2Docetaxel 2Cytoreduction Surgical Procedures 2Bevacizumab 2ALT-803 2peposertib 1peginterferon alfa-2b 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma × cabozantinib × Clear all
NCT05136196 2026-06-05

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

Phase 2 Recruiting
150 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡